AGL 40.05 Increased By ▲ 0.05 (0.13%)
AIRLINK 130.60 Increased By ▲ 1.07 (0.83%)
BOP 6.79 Increased By ▲ 0.11 (1.65%)
CNERGY 4.62 Decreased By ▼ -0.01 (-0.22%)
DCL 9.08 Increased By ▲ 0.14 (1.57%)
DFML 43.30 Increased By ▲ 1.61 (3.86%)
DGKC 84.01 Increased By ▲ 0.24 (0.29%)
FCCL 33.05 Increased By ▲ 0.28 (0.85%)
FFBL 78.80 Increased By ▲ 3.33 (4.41%)
FFL 11.65 Increased By ▲ 0.18 (1.57%)
HUBC 110.85 Increased By ▲ 0.30 (0.27%)
HUMNL 14.68 Increased By ▲ 0.12 (0.82%)
KEL 5.45 Increased By ▲ 0.06 (1.11%)
KOSM 8.27 Decreased By ▼ -0.13 (-1.55%)
MLCF 39.80 Increased By ▲ 0.01 (0.03%)
NBP 60.90 Increased By ▲ 0.61 (1.01%)
OGDC 199.50 Decreased By ▼ -0.16 (-0.08%)
PAEL 26.71 Increased By ▲ 0.06 (0.23%)
PIBTL 7.83 Increased By ▲ 0.17 (2.22%)
PPL 160.15 Increased By ▲ 2.23 (1.41%)
PRL 26.80 Increased By ▲ 0.07 (0.26%)
PTC 18.42 Decreased By ▼ -0.04 (-0.22%)
SEARL 83.00 Increased By ▲ 0.56 (0.68%)
TELE 8.25 Decreased By ▼ -0.06 (-0.72%)
TOMCL 34.50 Decreased By ▼ -0.01 (-0.03%)
TPLP 9.06 No Change ▼ 0.00 (0%)
TREET 17.07 Decreased By ▼ -0.40 (-2.29%)
TRG 59.81 Decreased By ▼ -1.51 (-2.46%)
UNITY 27.55 Increased By ▲ 0.12 (0.44%)
WTL 1.42 Increased By ▲ 0.04 (2.9%)
BR100 10,540 Increased By 133.8 (1.29%)
BR30 31,923 Increased By 209.9 (0.66%)
KSE100 98,275 Increased By 946.8 (0.97%)
KSE30 30,567 Increased By 374.2 (1.24%)

Oxford vaccine

Britain recommends not using Oxford/AstraZeneca vaccine for under-30s
World

Britain recommends not using Oxford/AstraZeneca vaccine for under-30s

  • "We are not advising a stop to any vaccination for any individual in any age group. We are advising a preference for one vaccine over another vaccine for a particular age group, really out of the utmost caution, rather than because we have any serious safety concerns," he said at a briefing. It came after Britain's MHRA medicine regulator identified a possible side-effect from the COVID-19 vaccine developed by Oxford University and AstraZeneca involving rare brain blood clotting.
Published 07 Apr, 2021 08:09pm
AstraZeneca/Oxford vaccine more effective with longer dose gap: study
Business & Finance

AstraZeneca/Oxford vaccine more effective with longer dose gap: study

  • The study confirmed the Anglo-Swedish drugmaker's findings from earlier this month that showed the vaccine had 76% efficacy against symptomatic coronavirus infection for three months after the first dose.
  • Efficacy was found to be at 81% with the longer interval of 12 weeks between the first and second dose, compared with 55% efficacy up to the six-week gap.
Published 19 Feb, 2021 09:17pm
South Africa offers AstraZeneca jabs to AU
World

South Africa offers AstraZeneca jabs to AU

  • "The first batch of Johnson & Johnson Covid-19 vaccines have arrived at OR Tambo International Airport," Mkhize tweeted as the precious cargo landed in the financial capital Johannesburg.
Published 17 Feb, 2021 11:06am